Integra LifeSciences (Nasdaq:IART) announced today that it named Stuart M. Essig as its president and CEO, effective May 1.
Essig, the company’s board chair, succeeds Mojdeh Poul in the corner office as he continues to serve as board chair.
“Stuart brings unmatched knowledge of Integra, its businesses, and its people,” said Barbara Hill, presiding director. “He combines deep institutional knowledge with a clear understanding of the work underway across the organization. We have full confidence in his leadership as Integra accelerates execution, strengthens customer and commercial focus, and builds on the important progress already underway across its priorities for 2026. The board believes this is the right leadership step for the company’s next phase, and as such, this is not an interim role, and we do not intend to initiate a CEO search.”
Poul intends to pursue “other opportunities,” according to a news release.
“I also want to thank Mojdeh for her numerous contributions to the company and for the meaningful progress made during her tenure,” said Essig. “Under her leadership, the company advanced several important strategic and operational priorities, including enterprise-wide portfolio and program prioritization, risk-based approach to quality remediation work, operational resiliency improvements, and the more recent transformation and business process optimization efforts. These initiatives are progressing well, and we remain fully committed to them.”
More about new CEO Stuart Essig
Essig brings more than 30 years of experience in medical technology and healthcare. He has served on Integra’s board since 1997 and became chair in June 2012. He also brings familiarity with the CEO role at the company, holding the post from 1997 through early 2012.
As he takes over as CEO, Essig says his focus centers on accelerating execution, strengthening customer and commercial focus and reinforcing a culture and operating. discipline. to drive sustained performance and deliver long-term shareholder value.
“I am honored to once again serve as Integra’s president and CEO,” said Mr. Essig. “I return with a clear mandate from the board and a long-term commitment to lead the company through its next chapter. In my role as executive chairman, I have seen firsthand the strength of our team and the meaningful progress underway across our priorities, particularly in quality, compliance, operational resilience, and the transformation of the organization.”
“I know this company, I understand what it takes to run it, and I am deeply committed to leading Integra forward.”
Integra also makes a move at chief commercial officer
Additionally, the company named Michael McBreen, its current EVP and president, Codman Specialty Surgical, as chief commercial officer (CCO).
In the newly created role, McBreen aims to help drive the company’s next phase of growth. The company said he will further elevate its commercial organization, with both divisions and the entire global comercial structure reporting to him.
“Mike is exceptionally well-suited for this role with deep commercial relationships,” Mr. Essig said. “He brings more than thirty years of commercial experience in the medical technology industry, and his appointment is an important part of how we move forward. This is a strategic leadership step that will help sharpen execution, strengthen our connection to our customers and markets, and support stronger performance across the Company. Integra intends to lead this next chapter with urgency, transparency, and a clear focus on execution.”
First-quarter results also reported
Integra LifeSciences also shared first-quarter results that came in ahead of the consensus forecast on Wall Street.
Shares of IART fell 2.7% to $10.65 apiece before the market opened today.
The Princeton, New Jersey-based medtech company reported losses of $4.6 million. That equals 6¢ per share on sales of $391.9 million for the three months ended March 31, 2026.
Integra recorded an 81.8% bottom-line gain on a sales increase of 2.4%.
Adjusted to exclude one-time items, earnings per share came in at 54¢. That landed 14¢ ahead of expectations on Wall Street. Sales also topped estimates as experts forecast $381.8 million in revenue.
Integra reiterated its 2026 sales guidance for between $1.662 billion and $1.702 billion. It increased its adjusted EPS guidance range from between $2.30 and $2.40 to between $2.40 and $2.50. The company said this increase reflects first-quarter benefits from IEEPA tariffs.
“Our first-quarter results reflected solid product demand and the continued impact of our transformation efforts. We are seeing improving performance across the organization as operational rigor and improved execution take hold,” said Essig. “During the quarter, we continued to drive improved supply reliability, supporting strong growth in Integra Skin and our return to market with PriMatrix and Durepair. We made meaningful progress at our state-of-the-art Braintree manufacturing facility and remain on track to begin production of SurgiMend by the end of June to support a fourth-quarter launch.
“Building on these efforts, we are focused on maintaining disciplined execution and remain confident in our ability to deliver our full-year commitments to our customers, patients, and shareholders.”